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Despite several loss of heterozygosity studies, a com-
prehensive genomic survey of pheochromocytomas
is still lacking. To identify DNA copy number changes
which might be important in tumor development and
progression and which may have diagnostic utility,
we evaluated genetic aberrations in 29 sporadic adre-
nal and extra-adrenal pheochromocytomas (19 clini-
cally benign tumors and 10 malignant lesions). Com-
parative genomic hybridization was performed using
directly fluorochrome-conjugated DNA extracted
from frozen (16) and paraffin-embedded (13) tumor
tissues. The most frequently observed changes were
losses of chromosomes 1p11–p32 (86%), 3q (52%), 6q
(34%), 3p, 17p (31% each), 11q (28%), and gains of
chromosomes 9q (38%) and 17q (31%). No amplifica-
tion was identified and no difference between adrenal
and extra-adrenal tumors was detected. Progression
to malignant tumors was strongly associated with de-
letions of chromosome 6q (60% versus 21% in clini-
cally benign lesions, P 5 0.0368) and 17p (50% versus
21%). Fluorescence in situ hybridization confirmed
the comparative genomic hybridization data of chro-
mosomes 1p, 3q, and 6q, and revealed aneuploidy in
some tumors. Our results suggest that the develop-
ment of pheochromocytomas is associated with spe-
cific genomic aberrations, such as losses of 1p, 3q,
and 6q and gains of 9q and 17q. In particular, tumor
suppressor genes on chromosomes 1p and 3q may be
involved in early tumorigenesis, and deletions of
chromosomes 6q and 17p in progression to malig-
nancy. (Am J Pathol 2000, 157:353–359)
Pheochromocytomas (PCCs) represent neuroendocrine
tumors derived from pheochromocytes within and out-
side the adrenal medulla. PCCs usually produce cat-
echolamines and, as a result of inappropriate hormone
secretion, can cause life-threatening disorders, such as
myocardial infarction and cerebrovascular hemorrhage.
To date no reliable clinical or histopathological mark-
ers are available to distinguish benign from malignant
PCCs. Metastases, occurring in approximately 10% of
the tumors, are the only convincing sign of malignancy.
They may already be present at the time of diagnosis or
occur only after lag phases as long as 25 to 30 years.1
Such a situation calls for more accurate markers that can
predict the clinical behavior of these tumors.
The genetic mechanisms underlying the tumorigenesis
of PCCs are poorly understood. Because of the known
association with the inherited tumor syndromes multiple
endocrine neoplasia type 2 (MEN2), Von Hippel-Lindau
disease (VHL) and neurofibromatosis type 1 (NF1),2–4
PCCs have been investigated for involvement of the re-
sponsible RET, VHL, and NF1 genes, respectively.5–9
However, only a subset of sporadic lesions harbors so-
matic mutations in these genes, suggesting that they do
not play a prominent role in PCC tumorigenesis.10–13
Furthermore, no mutation has been detected in the c-mos
proto-oncogene or in the p16 tumor suppressor gene
(TSG) in benign and malignant lesions.14,15 Conflicting
results exist with regard to the frequency of TP53 gene
alterations in PCCs as well as for the association of
c-erbB-2 expression with malignancy.16–19 Other onco-
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genes that have been found to be overexpressed in
PCCs, include c-myc, c-fos, and Bcl-2.19,20
Several loss of heterozygosity (LOH) studies provided
evidence for involvement of TSGs on chromosomes 1p,
3p, 11p, 17p, and 22q.21–25 However, the impact of these
data are limited, since small series of sporadic PCCs
were analyzed and often no correlation with clinical data
was presented. Moreover, the vast majority of the ge-
nome remains unexamined. We performed comparative
genomic hybridization (CGH) analysis on 29 apparently
sporadic PCCs, including 19 benign and 10 malignant
lesions, to identify chromosome alterations which may be
important in tumor development and behavior and might
have diagnostic utility. Additionally, fluorescence in situ
hybridization (FISH) experiments were carried out to in-
dependently confirm some of the CGH data.
Materials and Methods
Patients and Tumor Samples
Altogether, tumors of 29 patients with an apparently
sporadic adrenal (n 5 25) or extra-adrenal (n 5 4) PCC
were analyzed, including 19 clinically benign and 10
proven malignant lesions (with metastases). A pheochro-
mocytoma was considered sporadic if there was no fam-
ily history of MEN2, VHL, or its constituent tumors and
there were no other signs of MEN 2, VHL, or NF1 re-
corded by the clinician. Furthermore, previous analyses
did not reveal germline mutations in the RET and VHL
gene in these tumors10,11 (Dannenberg et al, unpub-
lished data). The average age of the patients was 50.3
years (range: 23–79) and the mean size of the tumors
was 7.1 6 4.6 cm for benign lesions and 11.0 6 4.7 cm
for malignant lesions. Nine of 19 benign and 7 of 10
malignant tumors were from female patients. Except for
two lymph node metastases, all specimens were primary
tumors. Clinical follow-up was obtained in all benign
cases with an average follow-up period of 7.6 years. Rele-
vant characteristics of all patients are listed in Table 1.
DNA Extraction
Genomic DNA from 16 frozen tumors was isolated
using the D-5000 Puregene DNA isolation kit (Gentra
Systems, Minneapolis, MN). DNA extraction from 13 for-
Table 1. Patient Characteristics and Genetic Findings in Sporadic Pheochromocytomas
Type/no. Age/Sex
Size
(cm) Location
CGH results
IHC
p53*
FISH results
Number of changes Chromosomal changes
of chromosomes
1, 3, 6, 9, and 17
1p22† 1p36† 3q26† 6q22†
All Gain Loss
Benign
1 63/F 4.7 EA 4 1 3 1p11-312, 3p2, 9q33-qter1
2 29/F 18 L 6 3 3 1p11-312, 3p2, 9q33-qter1, 17pq1
3 49/M 13 Bl 7 2 5 1p2, 3pq2, 17p2, 17q1
4 34/M 6 L 4 0 4 3pq2, 9q33-qter1 dis/tetras dis/tetras monos/dis dis/tetras
5 75/F 5 EA 6 2 5 1p11-322, 17pq1 4-2 4-2 tetras tetras
6 52/F 5 R 9 4 2 9q32-341
7 43/F 3 R 3 1 2 1p11-322, 3q2, 9q32-qter1
8 42/M 6 L 5 1 4 1p11-322, 3q2, 6q2, 9q32-qter1 2-1/4-2 dis/tetras 2-1/4-2 2-1/4-2
9 53/M nk L 4 0 4 1p11-312
10 27/F 11 L 6 2 4 1p2, 3pq2, 9q32-qter1, 17q1
11 72/F nk R 14 2 12 1p11-322, 3pq2, 6q2, 9q33-qter1, 17q1
12 43/M 6 R 3 0 3 1p11-312, 3q21-qter2, 17p2
13 42/M 4.5 R 3 0 3 1p11-352, 3q2 2
14 45/F 2.5 L 7 2 5 1p11-312, 6q2, 17q22-qter1 2
15 66/M 3.2 L 6 1 5 1p2, 3pq2, 17p2 2
16 79/M 5 R 5 1 4 1p11-352, 3pq2 2
17 51/F 5 L 3 0 3 1p11-322, 3q2, 6q2 2
18 57/M 15 nk 1 0 1 2
19 47/M nk EA 4 0 4 1p2, 3q2, 17pq2 2
Malignant
20 49/F 4 Meta., LN 5 2 3 1p11-312, 3q2, 6q2, 9q33-qter1, 17q22-qter1 1
21 36/M nk nk 1 0 1 1p11-212
22 43/F nk Meta., LN 5 0 5 1p2, 3q2, 6q2, 17pq2 2-1 2-1 2-1 2-1
23 36/M 21 EA 3 1 2 1p11-312, 9q32-qter1
24 70/F 16 L 6 0 6 1p31-pter2, 6q2, 17p2 2
25 65/F 11 R 13 6 7 1p11-312, 9pq11-332, 17p2, 17q23-qter1 1
26 56/F 8.5 L 21 13 8 1p2, 3p2, 3q1, 6q2, 9pq1, 17pq2 1
27 23/F 8 nk 4 2 2 1p11-322, 3q2, 17q1 2
28 62/F 12 L 16 9 7 6q2 2
29 49/M 7.5 R 8 0 8 1p2, 6q22-qter2, 17p2 2
*Data previously published (Ref. 20).
†In combination with the chromosome-specific centromere probe.
Abbreviations: M, male; F, female; L, left adrenal gland; R, right adrenal gland; Bl, bilateral adrenal localization; EA, extra-adrenal localization;
Meta., metastasis; LN, lymph node; nk, not known; n, no detectable changes; monos, monosomy; dis, disomy; tetras, tetrasomy; 4-2, tetrasomy with
only two copies (loss) of the specific region; 2-1, disomy with allelic loss of the specific region.
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malin-fixed, paraffin-embedded samples was performed
by standard detergent-proteinase K lysis, followed by
phenol/chloroform extraction and ethanol precipitation,
as described elsewhere.26
CGH and Digital Image Analysis
CGH was carried out as previously described.26 One
mg of high molecular weight tumor DNA was labeled with
Spectrum Green-dUTPs (Vysis, Downers Grove, IL) by
nick translation (BioNick kit, Life Technologies, Basel,
Switzerland). Archival tumor DNA with fragment sizes of
,1 kb was labeled with a platinum/D-Green complex
(D-Green-ULS) using the Kreatech Universal Linkage
System (ULS) D-Green labeling kit (kindly provided by
Kreatech Morwell Diagnostics GmbH, Zu¨rich, Switzer-
land), according to the manufacturer’s recommenda-
tions. Briefly, 800 ng of tumor DNA and 1.6 ml of D-Green-
ULS, adjusted to a total volume of 20 ml, was incubated at
65°C for 20 minutes. To reduce background signals, the
ULS-labeled samples were purified using Qiagen nucleo-
tide removal columns (Qiagen GmbH, Hilden, Germany).
The hybridization mixture consisted of 200 ng of Spec-
trum (or D-) Green-labeled tumor DNA, 200 ng of Spec-
trum Red-labeled sex matched normal reference DNA
(Vysis), and 10 to 20 mg of human Cot-1 DNA (Life
Technologies) dissolved in 10 ml of hybridization buffer
(50% formamide, 10% dextran sulfate, 2X SSC, pH 7.0).
Hybridization to normal metaphase spreads (Vysis) took
place for 3 days at 37°C.
Digital images were collected from six to seven met-
aphases using a Photometrics cooled CCD camera (Mi-
croimager 1400; Xillix Technologies, Vancouver, Cana-
da). The QUIPS software program (Vysis) was used to
calculate average green-to-red ratio profiles of at least
four observations per autosome and two observations
per sex chromosome in each analysis. Gains and losses
of DNA sequences were defined as chromosome regions
where the mean green-to-red fluorescence ratio was
above 1.20 and below 0.80, respectively. Over-represen-
tations were considered amplifications when the fluores-
cence ratio values in a subregion of a chromosome arm
exceeded 1.5. Because of some false positive results at
chromosomes 1p32-pter, 16p, 19, and 22 found in nor-
mal tissues, gains of these known G-C-rich regions were
excluded from all analyses.
FISH Analysis
To validate CGH data independently, touch prepara-
tions of four frozen PCCs were subjected to fluorescence
in situ hybridization (FISH) analysis using a chromosome
1-specific centromere probe (pUC1.77) in combination
with an 1p22–31-specific YAC probe (929-E-1) (kindly
provided by S. Franke, Center for Human Genetics, Uni-
versity of Leuven, Belgium and J.R. Testa, Fox Chase
Cancer Center, Philadelphia, PA), or a repeat probe
(p179), mapping to the 1p36 region.27–29 Chromosomes
3 and 6 were examined using a chromosome 3 (pa3.5)
and 6 (p308) centromere probe, in combination with a
3q26-specific (pancpin) and 6q22-specific (cCI6–44)
probe, respectively.30–33 Cell processing, probe label-
ing, in situ hybridization, and detection of the hybridized
signals were performed as recently described.34 For
each tumor, hybridization signals of 100 interphase nu-
clei were scored. Numerical chromosomal aberrations
were considered an aneusomy when the percentage of
nuclei showing an abnormal number of centromere sig-
nals exceeded 30%. The presence of only half of the
locus specific signals compared to the number of cen-
tromere signals in more than 30% of the nuclei was
interpreted as a deletion.
Statistical Analysis
To calculate the statistical significance of differences in
genomic changes between benign and malignant tumors,
we used contingency table analysis, which was also used to
analyze the relationship between genomic alterations and
sex. Regression analysis was carried out to compare the
number of chromosomal aberrations with tumor size.
Results
Overview of CGH Findings
Figure 1A summarizes all DNA copy number changes
identified in the 29 evaluated sporadic PCCs. Genetic
alterations were observed in all PCCs, and the average
number of chromosome arm aberrations per tumor was
6.3 6 4.4 (range, 1–21). Chromosomal losses (mean, 4.3;
range, 1–12) were more frequent than gains (mean, 1.9;
range, 0–13) and no amplifications could be detected
(Table 1). The average number of chromosomal alter-
ations was marginally associated with malignancy (5.3 6
2.7 versus 8.2 6 6.1), principally due to a higher fre-
quency of gains. The most common chromosome arm
copy number changes included losses of chromosomes
1p11-p32 (86%), 3q (52%), 6q (34%), 3p, 17p (31%
each), and 11q (28%), and gains of chromosome 9q
(38%) and 17q (31%). Representative examples of CGH
results are shown in Figure 1B.
Genetic Changes in Relation to Clinical
Parameters
Ten of 29 PCCs fell into the category of malignant
tumors, since regional or distant metastases occurred in
these patients. In these lesions, losses of chromosome
6q were more often observed as compared to clinically
benign lesions (60% versus 21%, P 5 0.0368). To a lesser
degree, losses of 17p were also related to metastatic
disease (50% versus 21%), whereas deletions of chromo-
some 3p and 3q were preferably associated with benign
tumors (42% versus 10% and 63% versus 30%, respec-
tively). Although the malignant tumors were significantly
larger in size (11.0 6 4.7 cm versus 7.1 6 4.6 cm, P 5
0.0470) and demonstrated a slightly higher number of
chromosome arm copy number changes, there was no
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correlation between the number of genomic aberrations
and the tumor size. No differences were seen between
adrenal and extra-adrenal PCCs.
Additionally, a statistically significant correlation was
found between the number of chromosomal alterations
and female gender (P 5 0.0196), predominantly due to a
higher frequency of gains of different genomic regions.
Comparison of CGH and FISH
FISH analysis confirmed the CGH results of chromo-
somes 1p, 3q, and 6q in 4 tumors that showed chromo-
somal imbalances as detected by CGH (Table 1). Two of
the 4 tumors presented with a partial loss of chromosome
1p (1p11–32). In one case, FISH analysis proved the loss
of this region and the retention of 1p36. However, the
other tumor appeared to have a complete loss of chro-
mosome 1p, which could be expected, since the 1p32-
pter region is known to generate some false positive
results in CGH.
In addition, the three benign lesions revealed a tetra-
somy in the major population of cells for all chromosomes
analyzed. In contrast, the malignant tumor turned out to
be diploid. In two of the three aneuploid lesions a sub-
population of diploid tumor cells (as demonstrated by two
centromere signals and only one locus-specific signal
per nucleus) could also be detected. Examples of FISH
results are shown in Figure 1C.
Discussion
Our genome-wide survey of genetic alterations in spo-
radic benign and malignant PCCs identified specific ab-
errations associated with tumor initiation and progres-
sion, which might be useful in clinical diagnosis. Our
results highlight several novel chromosome regions that
may harbor genes critically involved in the pathogenesis
of sporadic PCCs. A high frequency of losses of chromo-
somes 1p and 3q in the benign tumors suggests that they
are important genetic events in early tumorigenesis. De-
letions of chromosome 6q were strongly associated with
metastatic disease and thus may help to define the ma-
lignant potential of PCCs.
The most commonly encountered chromosomal aber-
rations in our series of 29 sporadic PCCs involved 1p, 3q,
9q, 6q, 3p, 17p, 17q, and 11q. These findings support
and extend the hypothesis of Koshla et al22 that multiple
genes are involved in the pathogenesis of these tumors.
Although LOH studies have shown loss of heterozygosity
at 1p, 3p, 11q, 17p, and 22q in syndrome-related and
sporadic PCCs,21–25 the here found losses of 3q and 6q
and gains of 9q and 17q have not been reported previ-
ously. In contrast to a previous LOH analysis,25 we ob-
served only one tumor with loss of 22q. Possible expla-
nations for this discrepancy are the limited sensitivity of
CGH for small losses (,10 Mb) and the fact that G-C-rich
chromosome regions, like those in chromosome 22, are
known to yield false positive CGH results.
We and others21–24 found a very high incidence of 1p
loss in PCCs, suggesting that it might be an important
tumorigenic event. Deletions of chromosome 1p are
common in several other human neoplasms, including
adrenocortical carcinomas and neurectodermally de-
rived tumors, such as neuroblastomas.35,36 The smallest
common region of overlap as detected by CGH in our
study involves the 1p22–32 region. Because of known
false positive CGH results at 1p32-pter, we verified the
CGH data by FISH using a probe mapping to 1p36. Our
observations indicate that some PCCs indeed exhibit a
partial loss of chromosome 1p. This correlates well with
the results of others,23,37 who found evidence for a po-
tential PCC tumor suppressor locus in the middle of the
short arm of chromosome 1. There are multiple candidate
TSGs in this region, including TGFb-R3, p18INK4C, and
PTPRF, none of which has been proven to be relevant in
PCC tumorigenesis. One should also consider the possi-
bility that more than a single TSG on 1p contributes to the
development of PCCs.
Another interesting finding of our study is the frequent
loss of chromosome 3q in PCCs, which is more often
encountered in benign than in malignant tumors. This
might point to diverging pathways in the development of
benign and malignant PCCs, although it is known that in
malignant tumors duplications of chromosome arms can
occur.38 In that case, LOH will not be detected by CGH.
However, it is certainly conceivable that loss of chromo-
some 3q is an early genetic event in the pathogenesis of
PCCs. Thus far, frequent allelic loss of chromosome 3q
has been demonstrated only in osteosarcoma, with a
putative TSG localized to a region between 3q26.2 and
3q26.3.39 The possible relationship of this candidate TSG
for PCC development however, is not clear.
Data on the genetic events that determine the malig-
nant potential of PCCs are scarce. We observed a strong
association of losses of chromosome 6q with advanced
disease stage. Frequent allelic imbalances at 6q have
also been reported in other malignancies40,41 and ap-
pear to be related to poor prognosis or metastatic dis-
ease in certain tumors.42,43 Although these data are sug-
gestive of the existence of several TSGs at 6q, none has
been identified so far. In addition, underrepresentations
of chromosome 17p were often observed in metastasiz-
ing lesions. 17p13 contains the TP53 gene, the TSG most
commonly involved in human carcinogenesis. Fourteen
of 29 PCCs evaluated in the present study have previ-
ously been immunohistochemically investigated for TP53
Figure 1. Summary of all DNA copy number changes detected by CGH in 19 benign and 10 malignant sporadic PCCs (A). The vertical green lines on the right
side of the chromosome ideograms indicate gains, the red on the left losses of the corresponding chromosome region. B: Individual representative examples of
CGH digital images (left) and fluorescent ratio profiles (right) illustrating genomic alterations of chromosomes 1 (loss of 1p11–32 with gain of the C-G rich
telomeric region), 3 (loss of 3q), 6 (loss of 6q), and 9 (gain of 9q33–34). C: Results of FISH analysis. I and II: interphase touch preparations of tumor number 8
analyzed using a centromeric probe for chromosome 1 (red signals) in combination with a 1p22–31-specific probe (green signals) (I) or a 1p36-specific probe
(II), demonstrating aneuploidy of this tumor with loss of the 1p22–31 locus (I) but not of the 1p36 locus (II). III: Monosomy of chromosome 3 in case 4. IV: Diploid
malignant tumor, showing the two copies of centromere 6 (red signals) and only one copy of the 6q22-specific locus (green signal), indicating loss of 6q.
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accumulation.20 Comparison of these results with our
CGH results (Table 1), indicates that TP53 alterations
may play a role in a subset of these tumors. Involvement
of another TSG on 17p, however, cannot be ruled out and
one candidate gene could be the putative TSG at the
medulloblastoma locus 17p13.3.44 Interestingly, three
malignant PCCs exhibited simultaneous gains of chromo-
somes 5p, 7p and 12q, similar to findings for malignant
endocrine pancreatic tumors.45
In conclusion, our results indicate that the develop-
ment of PCCs is associated with specific genetic alter-
ations, of which deletions of chromosome 1p (1p22–32)
and 3q are early genetic events. Losses involving chro-
mosome 3q (minimal overlapping region, 3q21-qter) and
6q (6q22-qter) and over-representations of chromosome
9q (9q33–34) and 17q point to new regions that may
contain PCC TSGs and oncogenes in addition to the
previously reported TSG loci 1p, 3p, 11q, 17p, and 22q.
Further studies are required to narrow down the critical
regions in each identified chromosome and to character-
ize the putative genes involved in tumor initiation and
progression of sporadic PCCs.
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